Researchers at the University of Maryland School of Medicine developed a new nanoparticle drug formulation that targets a specific receptor on cancer cells and appears to be more effective than a standard nanoparticle therapy currently on the market to treat metastatic breast cancer.
In a phase III randomized clinical trial, patients with prostate cancer assigned to eat seven or more servings of vegetables and fruits daily saw no extra protection from the increased consumption of micronutrients.
The phase III KEYNOTE-604 trial investigating Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy, met one of its dual primary endpoints of progression-free survival in the first-line treatment of patients with extensive stage small cell lung cancer.
Researchers at Yale and New York University found that state-mandated notifications on mammogram reports intended to inform women of the health risks related to breast density are not worded effectively.
Research in the January 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network uses data from the National Health Interview Survey from 2000 to 2017 to examine self-reported drinking habits among people reporting a cancer diagnosis.
For adult patients with brainstem high-grade gliomas, surgically removing the entire tumor may add many months or potentially years of survival beyond that offered by radiation and chemotherapy, according to results of a medical records study led by researchers at the Johns Hopkins Kimmel Cancer Center.
The National Comprehensive Cancer Network published new guidelines for treating children, adolescents and young adults with pediatric aggressive mature B-cell lymphomas, including Burkitt lymphoma and diffuse large B-cell lymphoma.
In a study of more than 1,600 patients with breast cancer undergoing chemotherapy, researchers found several associations between supplement use.
Treatment with the investigational single-agent belantamab mafodotin resulted in a 31% overall response rate with the 2.5 mg/kg regimen in patients with heavily pre-treated multiple myeloma.
A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma, easing concerns that these patients are at heightened risk for severe immune-related complications.